News | March 06, 2026
Alembic enters US branded market with first sales of Pivya UTI treatment
Pivya is Alembic’s first branded pharmaceutica product in the US and is being marketed through Alembic Therapeutics LLC
Pivya is Alembic’s first branded pharmaceutica product in the US and is being marketed through Alembic Therapeutics LLC
The inspection concluded with zero observations, confirming the facility's compliance with current Good Manufacturing Practices
The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
Recent data reveal that patients undergoing MWL are entering aesthetic practices with unique needs tied to facial structure and skin quality
Merck emphasized the broader significance of the findings
Our clinical data suggests ProLectin-M demonstrated earlier reductions in viral shedding compared with placebo with a favorable safety profile
The collaboration will leverage Medi Assist’s proprietary technology to streamline claims processing, enhance transparency, and deliver smarter health benefits to policyholders in the region
The decision marks a pivotal moment for the Massachusetts-based biotech giant
Subscribe To Our Newsletter & Stay Updated
